Next Article in Journal
Research Progress on Rolling Circle Amplification (RCA)-Based Biomedical Sensing
Next Article in Special Issue
Novel N4-Like Bacteriophages of Pectobacterium atrosepticum
Previous Article in Journal
Phytochemical Study of the Ecuadorian Species Lepechinia mutica (Benth.) Epling and High Antifungal Activity of Carnosol against Pyricularia oryzae
Previous Article in Special Issue
Computational Modelling of Large Scale Phage Production Using a Two-Stage Batch Process
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
Pharmaceuticals 2018, 11(2), 34; https://doi.org/10.3390/ph11020034

Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes through Complex Formulation

Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, SE-10691 Stockholm, Sweden
*
Authors to whom correspondence should be addressed.
Received: 20 March 2018 / Revised: 11 April 2018 / Accepted: 17 April 2018 / Published: 19 April 2018
(This article belongs to the Special Issue Phage Therapy and Phage-Mediated Biological Control)
Full-Text   |   PDF [459 KB, uploaded 3 May 2018]

Abstract

The resurgence of research into phage biology and therapy is, in part, due to the increasing need for novel agents to treat multidrug-resistant infections. Despite a long clinical history in Eastern Europe and initial success within the food industry, commercialized phage products have yet to enter other sectors. This relative lack of success is, in part, due to the inherent biological limitations of whole phages. These include (but are not limited to) reaching target sites at sufficiently high concentrations to establish an infection which produces enough progeny phages to reduce the bacterial population in a clinically meaningful manner and the limited host range of some phages. Conversely, parallels can be drawn between antimicrobial enzymes derived from phages and conventional antibiotics. In the current article the biological limitations of whole phage-based therapeutics and their derived antimicrobial enzymes will be discussed. In addition, the ability of more complex formulations to address these issues, in the context of medical and non-medical applications, will also be included. View Full-Text
Keywords: bacteriophage; pharmacology; synergy; formulation; combination therapy; product development bacteriophage; pharmacology; synergy; formulation; combination therapy; product development
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Cooper, C.J.; Koonjan, S.; Nilsson, A.S. Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes through Complex Formulation. Pharmaceuticals 2018, 11, 34.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top